1. Home
  2. MARPS vs AIM Comparison

MARPS vs AIM Comparison

Compare MARPS & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MARPS
  • AIM
  • Stock Information
  • Founded
  • MARPS 1956
  • AIM 1966
  • Country
  • MARPS United States
  • AIM United States
  • Employees
  • MARPS N/A
  • AIM N/A
  • Industry
  • MARPS Oil & Gas Production
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MARPS Energy
  • AIM Health Care
  • Exchange
  • MARPS Nasdaq
  • AIM Nasdaq
  • Market Cap
  • MARPS 7.8M
  • AIM 8.8M
  • IPO Year
  • MARPS N/A
  • AIM N/A
  • Fundamental
  • Price
  • MARPS $3.92
  • AIM $0.12
  • Analyst Decision
  • MARPS
  • AIM Strong Buy
  • Analyst Count
  • MARPS 0
  • AIM 2
  • Target Price
  • MARPS N/A
  • AIM $2.75
  • AVG Volume (30 Days)
  • MARPS 2.6K
  • AIM 476.8K
  • Earning Date
  • MARPS 01-01-0001
  • AIM 03-27-2025
  • Dividend Yield
  • MARPS 8.44%
  • AIM N/A
  • EPS Growth
  • MARPS N/A
  • AIM N/A
  • EPS
  • MARPS 0.30
  • AIM N/A
  • Revenue
  • MARPS $945,496.00
  • AIM $170,000.00
  • Revenue This Year
  • MARPS N/A
  • AIM N/A
  • Revenue Next Year
  • MARPS N/A
  • AIM $1,693.10
  • P/E Ratio
  • MARPS $13.05
  • AIM N/A
  • Revenue Growth
  • MARPS N/A
  • AIM N/A
  • 52 Week Low
  • MARPS $3.76
  • AIM $0.11
  • 52 Week High
  • MARPS $6.50
  • AIM $0.62
  • Technical
  • Relative Strength Index (RSI)
  • MARPS 51.16
  • AIM 42.13
  • Support Level
  • MARPS $3.85
  • AIM $0.11
  • Resistance Level
  • MARPS $3.95
  • AIM $0.16
  • Average True Range (ATR)
  • MARPS 0.03
  • AIM 0.01
  • MACD
  • MARPS 0.01
  • AIM 0.00
  • Stochastic Oscillator
  • MARPS 52.94
  • AIM 5.00

About MARPS Marine Petroleum Trust Units of Beneficial Interest

Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Share on Social Networks: